Abstract
The inhibitory effect of nomifensine (Norn; 200 mg orally) on prolactin (PRL) secretion was studied in 15 subjects with puerperal hyperprolactinemia and in 59 pathologic hyperprolactinemic women. The latter were grouped as follows: i) patients with surgically proven PRL secretory pituitary adenomas (proven tumors; 27 cases); ii) patients presenting radiological signs of sella indicative of a pituitary tumor (presumptive tumors; 10 cases); iii) subjects with non-drug induced hyperprolactinemia (hyperprolactinemia of uncertain etiology; 22 cases). A mean PRL fall of 30% or more of baseline hormone levels in samples collected within the 120–240 min post-treatment interval was adopted to define responsiveness to Norn. In 24 out of 27 subjects with proven tumors and in 9 out of 10 subjects with presumptive tumors Norn did not induce significant variations in PRL secretion. In only 11 % of the patients with surgery-confirmed or highly suspected tumors a hormone decrease greater than 30% was observed. In addition, 13 subjects with hyperprolactinemia of uncertain etiology did not respond to Norn administration. In 5 of these, additional data suggesting the existence of an adenoma were collected. Finally, 3 out of 9 Nom-responder patients presented either a polycystic ovary syndrome or transitory hyperprolactinemia. The finding that hyperprolactinemic women, who did not show clinical or radiological signs of a tumor and patients with highly presumptive or proven pituitary tumors may present comparable responses to Norn, suggests that this pattern may be indicative of an early manifestation of a PRL-secreting adenoma which has yet to evolve. The follow-up of Nom-non-responder hyperprolactinemic subjects who did not show clinical signs of harboring a tumor, is therefore advisable.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Faglia G., Giovanelli M.A., McLeod R.M. Pituitary microadenomas. Academic Press, New York, 1980.
Burrow G.N., Wortzman G., Rewcastle N.B., Holgate R.C., Kovacs K. Microadenomas of the pituitary and abnormal tomograms in an unselected autopsy series. N. Engl. J. Med. 304:156, 1981.
Franks S., Jacobs H.S. Characterization and management of hyperprolactinemic amenorrhea. In: Crosignani P.G., Robyn C. (Eds.), Prolactin and human reproduction. Academic Press, New York, 1977, p. 245.
Keye W.R. Jr., Chang R.J., Jaffe R.B. Hyperprolactinemic menorrhea. N. Engl. J. Med. 297:396, 1977.
Von Werder K., Fahlbusch R., Landraf R., Pickardt C.R., Rjosh H.K., Scriba P.C. Treatment of patients with prolactinomas. J. Endocrinol. Invest. 1:47, 1978.
Braestrup C., Scheel-Kruger J. Methylphenidate-like effect of the new antidepressant drug nomifensine (HOE 984). Eur. J. Pharmacol. 38:305, 1976.
Hunt P., Kannangiesser M.H., Reynaud J.P. Nomifensine a new potent inhibitor of dopamine uptake into synaptosomes from rat corpus striatum. J. Pharm. Pharmacol. 26:370, 1974.
Camanni F., Genazzani A.R., Massara F., De Leo V., Molinatti G.M., Müller E.E. Prolactin responsiveness to nomifensine in patients with hyperprolactinemia of tumorous or uncertain etiology. J. Clin. Endocrinol. Metab. 51:650, 1980.
Genazzani A.R., Camanni F., Massara F., Picciolini F., Cocchi D., Belforte L., Müller E.E. A new pharmacological approach in the diagnosis of hyperprolactinemic states: the nomifensine test. Acta Endocrinol. (Kbh.) 93:139, 1980.
Genazzani A.R., De Leo V., Murru S., Cocchi D., Camanni F., Müller E.E. Dynamic tests of prolactin secretion in hyperprolactinemic states: carbidopa-L-dopa and indirectly acting dopamine agonists. J. Clin. Endocrinol. Metab. 54:429, 1982.
Kamoi K., Tchuchida I., Sato H., Tanaka R., Ishiguro T., Kaneko K., Iwasaki Y., Shibata A. Comparison of the responses in the nomifensine test with hyperprolactinemia dueto prolactin-secreting pituitary tumors and nonprolactin-secreting hypothalamic tumors. J. Clin. Endocrinol. Metab. 53:1285, 1981.
Müller E.E., Genazzani A.R., Murru S. Nomifensine: diagnostic test in hyperprolactinemic states. J. Clin. Endocrinol. Metab. 47:1352, 1978.
Crosignani P.G., Ferrari C., Malinverni A., Barbieri C., Maltei A.M., Caldara R., Rocchetti M. Effect of central nervous system dopaminergic activation on prolactin secretion in man: evidence for a common central defect in hyperprolactinemic patients with and without radiological signs of pituitary tumors. J. Clin. Endocrinol. Metab. 51:1068, 1980.
D’Agata R., Aliffi A., Vicari E., Volpicelli D., Mongioi A., Gulizia S. Some critical considerations on the use of nomifensine test in the hyperprolactinemic syndrome. Horm. Res. 14:148, 1981.
Ferrari C., Crosignani P.G., Caldara R., Picciotti M.C., Malinverni A., Barattini B., Rampini P., Telloli P. Failure of nomifensine administration to’discriminate between tumorous and nontumorous hyperprolactinemia. J. Clin. Endocrinol. Metab. 50:23, 1980.
Moriondo P., Travaglini P., Nissim M., Faglia G. Evaluation of two inhibitory tests (nomifensine and L-Dopa + carbidopa) for the diagnosis of hyperprolactinemic states. Clin. Endocrinol. (Oxf.) 13:525, 1980.
Cocchi D., Locatelli V., Picciolini E., Genazzani A.R., Müller E.E. Prolactin-lowering effect of nomifensine in the rat. Proc. Soc. Exp. Biol. Med. 162:38, 1979.
Frohman L.A., Berelovitz H., Gonzales C., Barowsky H., Rao S., Lim V.S., Frohman M.A., Thominet J.L. Recent advances in the study of dopaminergic mechanisms in hyperprolactinemic states. In: Crosignani P.G., Rubin B. (Eds.), International symposium on endocrinology of human infertility: New aspects. Academic Press, New York, 1980, p. 39.
Assies J., Schellekens A.P.M., Touber J.L. The value of an intravenous TRH test for the diagnosis of tumoral prolactinemia. Acta Endocrinol. (Kbh.) 94:439, 1980.
Bercovici J.P., Khoury S., Tater D., Caroff J., Sudre Y., Besson G. Domperidone: un nouvel agent pharmacodynamique pour l’exploration hypophysaire. Nouv. Presse Med. 10:2421, 1981.
Pontiroli A.E., Falsetti L., Voltolini A.M., Alberetto M., Pellicciotta G., De Pasqua A., Girardi A.M., Pozza G. Benserazide, a stimulator of prolactin release: a new test in the diagnosis of pituitary prolactin-secreting tumours. Acta Endocrinol. (Kbh.) 98:326, 1981.
Scanion M.F., Rodriguez-Arnao M.D., McGregor A.M., Wightman D., Lewis M., Cook D.B., Gomez-Pan A., Hall R. Altered dopaminergic regulation of thyrotrophin release in patients with prolactinomas: comparison with other tests of hypothalamic-pituitary function. Clin. Endocrinol. (Oxf.) 14:133, 1981.
Lamberts S.W.J., Bikenhager J.C., Kwa H.G. Basal and TRH stimulated prolactin in patients with pituitary tumours. Clin. Endocrinol. (Oxf.) 5:709, 1976.
Mac Gregor C., Maldonado D., Canales E.S., Soria J., Zarate A. Prolactin responsiveness to TRH in amenorrheic women with and without galactorrhea. Acta Obstet. Gynecol. Scand. 56:333, 1977.
Jeske W. The effect of metoclopramide, TRH and L-dopa on prolactin secretion in pituitary adenoma and in “functional” galactorrhoea syndrome. Acta Endocrinol. (Kbh.) 91:385, 1979.
Tolis G. Galactorrhea-amenorrhea and hyperprolactinemia: pathophysiological aspects and diagnostic tests. Clin. Endocrinol. (Oxf.) (Suppl.) 6:815, 1977.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Minuto, F., Barbarino, A., Baviera, G. et al. Multicentric experience on the acute effect of nomifensine in hyperprolactinemic women. J Endocrinol Invest 7, 137–140 (1984). https://doi.org/10.1007/BF03348404
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03348404